Gilead Sciences, INC Form 4 insider transactions

Wettan Keeley M Cain, EVP Gen Counsel, Legal & Comp of Gilead Sciences, Inc., reported multiple transactions in common stock on August 10, 2026.

Daniel Patrick O'Day, Chairman & CEO and a Director of Gilead Sciences, Inc., sold 15,000 shares of common stock on August 3, 2026.

Andrew D Dickinson, Chief Financial Officer of Gilead Sciences, Inc., sold 3,000 shares of common stock on July 15, 2026 for $129.93 per share.

Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences, Inc., sold 3,000 shares of common stock on July 15, 2026 for $129.92 per share.

Gilead Sciences Chairman & CEO Daniel O'Day reported the sale of company stock under a pre-arranged trading plan.

Gilead Sciences Chief Commercial & Corporate Affairs Officer Johanna Mercier sold 3,000 shares of common stock via a 10b5-1 plan.

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Chief Medical Officer Dietmar Berger acquired 533 shares of Gilead Sciences common stock through the vesting of restricted stock units.

EVP and General Counsel Keeley M. Cain Wettan exercised restricted stock units and sold shares to cover tax obligations.

Gilead Sciences CFO Andrew D. Dickinson acquired 2,796 shares via restricted stock unit vesting and disposed of 1,341 shares to cover tax obligations.

Johanna Mercier, Chief Commercial & Corporate Affairs Officer at Gilead Sciences, reported the vesting and sale of restricted stock units.

Gilead Sciences Chairman and CEO Daniel O'Day acquired 8,779 shares through the vesting of restricted stock units.

Gilead Sciences Chairman and CEO Daniel O'Day sold 15,000 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Gilead Sciences acquired 471,698 additional shares of Assembly Biosciences at $26.50 per share.

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Johanna Mercier, Chief Commercial & Corporate Affairs Officer at Gilead Sciences, exercised options and sold 28,000 shares under a 10b5-1 plan.

Gilead Sciences Director Jeffrey Bluestone acquired 1,146 restricted stock units and 4,884 stock options on April 30, 2026.

Gilead Sciences Director Jacqueline K. Barton acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Director Sandra Horning of Gilead Sciences acquired 1,146 restricted stock units and 4,884 stock options on April 30, 2026, with immediate vesting.

Gilead Sciences Director Ted W. Love acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Javier Rodriguez, a Director at Gilead Sciences, Inc., acquired stock options and restricted stock units on April 30, 2026, as detailed in a recent SEC Form 4 filing.

Gilead Sciences Director Anthony Welters acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Gilead Sciences Director Harish Manwani acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Gilead Sciences Director Kelly A. Kramer acquired restricted stock units and stock options on April 30, 2026, as detailed in a Form 4 filing.

Gilead Sciences Chairman and CEO Daniel O'Day sold 10,000 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Gilead Sciences Chief Commercial & Corporate Affairs Officer Johanna Mercier sold 3,000 shares of common stock.

Gilead Sciences Chairman and CEO Daniel O'Day sold 10,000 shares of common stock for approximately $1.37 million as part of a Rule 10b5-1 trading plan.

Gilead Sciences' Chief Communications Officer, Johanna Mercier, sold 3,000 shares of GILD common stock at $144.23 per share.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, reported the sale of 3,000 shares of common stock at $144.23 per share, executed under a pre-arranged 10b5-1 trading plan.